echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA: Longest OS Results for the Treatment of Extensive Small Cell Lung Cancer by Slulizumab (ASTRUM-005 Study)

    JAMA: Longest OS Results for the Treatment of Extensive Small Cell Lung Cancer by Slulizumab (ASTRUM-005 Study)

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Small cell lung cancer accounts for about 15% to 20% of bronchial lung cancer, and is the most aggressive subtype of lung cancer, divided into limited small cell lung cancer (LS-SCLC) and ES-SCLC
    .


    On September 27, 2022, the ASTRUM-005 study, an international multicenter Phase 3 clinical study led by Professor Cheng Ying, was just published in the Journal of the American Medical Association (JAMA), one of the world's top four medical journals, becoming the world's first clinical study
    of small cell lung cancer immunotherapy to be published in the main journal of JAMA.


    ASTRUM-005 research is a phase III clinical study of Henlius's self-developed anti-PD-1 monoclonal antibody H drug Hansi-like (sluliumab) combined with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC ®), and after Professor Cheng Ying first reported the results at the 2022 ASCO Annual Meeting, it has attracted widespread attention
    from global peers.


    It is expected to benefit the world and fill the clinical gap

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.